07 February 2019
Visiongain has launched a new pharma report Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Regenerative medicine (RM) is viewed as possessing the ability to provide therapeutic products targeted at multiple disease classes, such as cardiovascular, dermatological, and orthopaedic conditions. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.
The lead analyst of the report commented "Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific. Partly, this is due to a desire to demonstrate excellence in national biotechnology industries, especially in emerging markets wanting to show progress in moving towards a knowledge-based economy. Governments are also concerned about obtaining a share in the global healthcare market of the future, when TRM products may be expected to overtake other types of treatment in the field of medicine, delivering both improved clinical outcomes and cost savings."
Leading companies featured in the report include Athersys, Inc., Avita Medical, AxoGen, Inc., MEDIPOST Co., Ltd., NuVasive, Astellas Pharma, Organogenesis Holdings Inc., Osiris Therapeutics, Inc. and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.